The DOI matches its Crossref record; 148 of the 148 references it cites were found in a registry or an index.
Genetic Markers in Triple-Negative Breast Cancer
Open accessAbstract
Triple-negative breast cancer (TNBC) accounts for 15% to 20% of breast cancer cases and is characterized by the absence of estrogen, progesterone, and human epidermal growth factor 2 receptors. Though TNBC is a highly heterogenic and aggressive disease, TNBC patients have better response to neoadjuvant therapy compared to other breast cancer subtypes. Nevertheless, patients with residual disease have a very poor prognosis, with higher probability of relapse and lower overall survival in the first years after diagnosis. TNBC has 6 subtypes with distinct molecular signatures with different prognoses and probably different responses to therapy. The precise stratification of TNBC is therefore crucial for the development of potent standardized and targeted therapies. In spite of intensive research into finding new molecular biomarkers and designing personalized therapeutic approaches, BRCA mutational status is the only clinically validated biomarker for personalized therapy in TNBC. Recent studies have reported several promising biomarkers that are currently being validated through clinical trials. The objective of this review was to summarize the clinically relevant genetic markers for TNBC that could serve as diagnostic, prognostic, or predictive or could improve personalized therapeutic strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
Molecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
Sørlie, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191367098 · Cited by 10,938
The biology of VEGF and its receptors
Ferrara, N., Gerber, H.-P., & LeCouter, J. (2003) · Nature Medicine · doi:10.1038/nm0603-669 · Cited by 9,591
A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
Paik, S., Shak, S., Tang, G., Kim, C., Baker, J., Cronin, M., Baehner, F. L., Walker, M. G., Watson, D., Park, T., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041588 · Cited by 6,277
The phosphoinositide 3-kinase pathway
Cantley, L. C. (2002) · Science · doi:10.1126/science.296.5573.1655 · Cited by 5,621
Lehmann, B. D., Bauer, J. A., Chen, X., Sanders, M. E., Chakravarthy, A. B., Shyr, Y., & Pietenpol, J. A. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45014 · Cited by 5,592
Repeated observation of breast tumor subtypes in independent gene expression data sets
Sørlie, T., Tibshirani, R., Parker, J., Hastie, T., Marron, J. S., Nobel, A., Deng, S., Johnsen, H., Pesich, R., Geisler, S., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0932692100 · Cited by 5,429
Triple-negative breast cancer: clinical features and patterns of recurrence
Dent, R., Trudeau, M., Pritchard, K. I., Hanna, W. M., Kahn, H. K., Sawka, C. A., Lickley, L. A., Rawlinson, E., Sun, P., & Narod, S. A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-3045 · Cited by 5,091
Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
Parker, J. S., Mullins, M., Cheang, M. C. U., Leung, S., Voduc, D., Vickery, T., Davies, S., Fauron, C., He, X., Hu, Z., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.1370 · Cited by 4,721
Race, Breast Cancer Subtypes, and Survival in the Carolina Breast Cancer Study
Carey, L. A., Perou, C. M., Livasy, C. A., Dressler, L. G., Cowan, D., Conway, K., Karaca, G., Troester, M. A., Tse, C. K., Edmiston, S., et al. (2006) · JAMA · doi:10.1001/jama.295.21.2492 · Cited by 3,819
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Robson, M., Im, S.-A., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., Delaloge, S., Li, W., Tung, N., Armstrong, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706450 · Cited by 3,294
Audeh, M. W., Carmichael, J., Penson, R. T., Friedlander, M., Powell, B., Bell-McGuinn, K. M., Scott, C., Weitzel, J. N., Oaknin, A., Loman, N., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60893-8 · Cited by 2,279
Metastatic Behavior of Breast Cancer Subtypes
Kennecke, H., Yerushalmi, R., Woods, R., Cheang, M. C. U., Voduc, D., Speers, C. H., Nielsen, T. O., & Gelmon, K. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.9820 · Cited by 2,262
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer
Prat, A., Parker, J. S., Karginova, O., Fan, C., Livasy, C., Herschkowitz, J. I., He, X., & Perou, C. M. (2010) · Breast Cancer Research · doi:10.1186/bcr2635 · Cited by 2,167
Bauer, K. R., Brown, M., Cress, R. D., Parise, C. A., & Caggiano, V. (2007) · Cancer · doi:10.1002/cncr.22618 · Cited by 2,067
Sotiriou, C., Neo, S.-Y., McShane, L. M., Korn, E. L., Long, P. M., Jazaeri, A., Martiat, P., Fox, S. B., Harris, A. L., & Liu, E. T. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1732912100 · Cited by 1,993
The clonal and mutational evolution spectrum of primary triple-negative breast cancers
Shah, S. P., Roth, A., Goya, R., Oloumi, A., Ha, G., Zhao, Y., Turashvili, G., Ding, J., Tse, K., Haffari, G., et al. (2012) · Nature · doi:10.1038/nature10933 · Cited by 1,967
Cancer Susceptibility and the Functions of BRCA1 and BRCA2
Venkitaraman, A. R. (2002) · Cell · doi:10.1016/s0092-8674(02)00615-3 · Cited by 1,713
Tutt, A., Robson, M., Garber, J. E., Domchek, S. M., Audeh, M. W., Weitzel, J. N., Friedlander, M., Arun, B., Loman, N., Schmutzler, R. K., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60892-6 · Cited by 1,655
Lehmann, B. D., Jovanović, B., Chen, X., Estrada, M. V., Johnson, K. N., Shyr, Y., Moses, H. L., Sanders, M. E., & Pietenpol, J. A. (2016) · PLOS ONE · doi:10.1371/journal.pone.0157368 · Cited by 1,426
Adams, S., Gray, R. J., Demaria, S., Goldstein, L., Perez, E. A., Shulman, L. N., Martino, S., Wang, M., Jones, V. E., Saphner, T. J., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.55.0491 · Cited by 1,299
Loi, S., Michiels, S., Salgado, R., Sirtaine, N., Jose, V., Fumagalli, D., Kellokumpu-Lehtinen, P.-L., Bono, P., Kataja, V., Desmedt, C., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu112 · Cited by 1,256
Sequence analysis of mutations and translocations across breast cancer subtypes
Banerji, S., Cibulskis, K., Rangel-Escareno, C., Brown, K. K., Carter, S. L., Frederick, A. M., Lawrence, M. S., Sivachenko, A. Y., Sougnez, C., Zou, L., et al. (2012) · Nature · doi:10.1038/nature11154 · Cited by 1,179
Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma
Livasy, C. A., Karaca, G., Nanda, R., Tretiakova, M. S., Olopade, O. I., Moore, D. T., & Perou, C. M. (2006) · Modern Pathology · doi:10.1038/modpathol.3800528 · Cited by 1,063
Denkert, C., von Minckwitz, G., Brase, J. C., Sinn, B. V., Gade, S., Kronenwett, R., Pfitzner, B. M., Salat, C., Loi, S., Schmitt, W. D., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.1967 · Cited by 1,026
von Minckwitz, G., Schneeweiss, A., Loibl, S., Salat, C., Denkert, C., Rezai, M., Blohmer, J. U., Jackisch, C., Paepke, S., Gerber, B., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70160-3 · Cited by 1,022
Sikov, W. M., Berry, D. A., Perou, C. M., Singh, B., Cirrincione, C. T., Tolaney, S. M., Kuzma, C. S., Pluard, T. J., Somlo, G., Port, E. R., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.0572 · Cited by 1,013
Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer
Silver, D. P., Richardson, A. L., Eklund, A. C., Wang, Z. C., Szallasi, Z., Li, Q., Juul, N., Leong, C.-O., Calogrias, D., Buraimoh, A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.4725 · Cited by 981
Germline BRCA1 Mutations and a Basal Epithelial Phenotype in Breast Cancer
Foulkes, W. D. (2003) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/djg050 · Cited by 970
Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial
Tutt, A., Tovey, H., Cheang, M. C. U., Kernaghan, S., Kilburn, L., Gazinska, P., Owen, J., Abraham, J., Barrett, S., Barrett-Lee, P., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0009-7 · Cited by 912
The Fanconi anaemia/BRCA pathway
D'Andrea, A. D., & Grompe, M. (2003) · Nature Reviews Cancer · doi:10.1038/nrc970 · Cited by 822
Re: Germline BRCA1 Mutations and a Basal Epithelial Phenotype in Breast Cancer
van der Groep, P., Bouter, A., van der Zanden, R., Menko, F. H., Buerger, H., Verheijen, R. H. M., van der Wall, E., & van Diest, P. J. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh114 · Cited by 798
Identification of molecular apocrine breast tumours by microarray analysis
Farmer, P., Bonnefoi, H., Becette, V., Tubiana-Hulin, M., Fumoleau, P., Larsimont, D., MacGrogan, G., Bergh, J., Cameron, D., Goldstein, D., et al. (2005) · Oncogene · doi:10.1038/sj.onc.1208561 · Cited by 785
Allred, D. C., Clark, G. M., Elledge, R., Fuqua, S. A. W., Brown, R. W., Chamness, G. C., Osborne, C. K., & McGuire, W. L. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.3.200 · Cited by 772
Gucalp, A., Tolaney, S., Isakoff, S. J., Ingle, J. N., Liu, M. C., Carey, L. A., Blackwell, K., Rugo, H., Nabell, L., Forero, A., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3327 · Cited by 749
Masuda, H., Baggerly, K. A., Wang, Y., Zhang, Y., Gonzalez-Angulo, A. M., Meric-Bernstam, F., Valero, V., Lehmann, B. D., Pietenpol, J. A., Hortobagyi, G. N., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0799 · Cited by 749
Aas, T., Børresen, A.-L., Geisler, S., Smith-Sørensen, B., Johnsen, H., Varhaug, J. E., Akslen, L. A., & Lønning, P. E. (1996) · Nature Medicine · doi:10.1038/nm0796-811 · Cited by 736
Lin, N. U., Vanderplas, A., Hughes, M. E., Theriault, R. L., Edge, S. B., Wong, Y., Blayney, D. W., Niland, J. C., Winer, E. P., & Weeks, J. C. (2012) · Cancer · doi:10.1002/cncr.27581 · Cited by 695
Couch, F. J., Hart, S. N., Sharma, P., Toland, A. E., Wang, X., Miron, P., Olson, J. E., Godwin, A. K., Pankratz, V. S., Olswold, C., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.1414 · Cited by 672
Atchley, D. P., Albarracin, C. T., Lopez, A., Valero, V., Amos, C. I., Gonzalez-Angulo, A. M., Hortobagyi, G. N., & Arun, B. K. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.6231 · Cited by 604
Molecular Characterization of Basal-Like and Non-Basal-Like Triple-Negative Breast Cancer
Prat, A., Adamo, B., Cheang, M. C. U., Anders, C. K., Carey, L. A., & Perou, C. M. (2013) · The Oncologist · doi:10.1634/theoncologist.2012-0397 · Cited by 568
Sandhu, S. K., Schelman, W. R., Wilding, G., Moreno, V., Baird, R. D., Miranda, S., Hylands, L., Riisnaes, R., Forster, M., Omlin, A., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70240-7 · Cited by 562
Cyclin E and Survival in Patients with Breast Cancer
Keyomarsi, K., Tucker, S. L., Buchholz, T. A., Callister, M., Ding, Y., Hortobagyi, G. N., Bedrosian, I., Knickerbocker, C., Toyofuku, W., Lowe, M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021153 · Cited by 557
Neoadjuvant Chemotherapy and Bevacizumab for HER2-Negative Breast Cancer
von Minckwitz, G., Eidtmann, H., Rezai, M., Fasching, P. A., Tesch, H., Eggemann, H., Schrader, I., Kittel, K., Hanusch, C., Kreienberg, R., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1111065 · Cited by 530
Enzalutamide for the Treatment of Androgen Receptor–Expressing Triple-Negative Breast Cancer
Traina, T. A., Miller, K., Yardley, D. A., Eakle, J., Schwartzberg, L. S., O’Shaughnessy, J., Gradishar, W., Schmid, P., Winer, E., Kelly, C., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.3495 · Cited by 530
Carey, L. A., Rugo, H. S., Marcom, P. K., Mayer, E. L., Esteva, F. J., Ma, C. X., Liu, M. C., Storniolo, A. M., Rimawi, M. F., Forero-Torres, A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.5579 · Cited by 499
Lehmann, B. D., & Pietenpol, J. A. (2014) · The Journal of Pathology · doi:10.1002/path.4280 · Cited by 495
The relationship between BcI2, Bax and p53: consequences for cell cycle progression and cell death
Basu, A. (1998) · Molecular Human Reproduction · doi:10.1093/molehr/4.12.1099 · Cited by 491
Triple-Negative Breast Cancer: Distinguishing between Basal and Nonbasal Subtypes
Rakha, E. A., Elsheikh, S. E., Aleskandarany, M. A., Habashi, H. O., Green, A. R., Powe, D. G., El-Sayed, M. E., Benhasouna, A., Brunet, J.-S., Akslen, L. A., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2132 · Cited by 489
Balko, J. M., Giltnane, J. M., Wang, K., Schwarz, L. J., Young, C. D., Cook, R. S., Owens, P., Sanders, M. E., Kuba, M. G., Sánchez, V., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0286 · Cited by 482
Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study
Copson, E. R., Maishman, T. C., Tapper, W. J., Cutress, R. I., Greville-Heygate, S., Altman, D. G., Eccles, B., Gerty, S., Durcan, L. T., Jones, L., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30891-4 · Cited by 481
Shen, Y., Rehman, F. L., Feng, Y., Boshuizen, J., Bajrami, I., Elliott, R., Wang, B., Lord, C. J., Post, L. E., & Ashworth, A. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1391 · Cited by 479
Dieci, M. V., Criscitiello, C., Goubar, A., Viale, G., Conte, P., Guarneri, V., Ficarra, G., Mathieu, M. C., Delaloge, S., Curigliano, G., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdt556 · Cited by 460
How basal are triple‐negative breast cancers?
Bertucci, F., Finetti, P., Cervera, N., Esterni, B., Hermitte, F., Viens, P., & Birnbaum, D. (2008) · International Journal of Cancer · doi:10.1002/ijc.23518 · Cited by 443
Isakoff, S. J., Mayer, E. L., He, L., Traina, T. A., Carey, L. A., Krag, K. J., Rugo, H. S., Liu, M. C., Stearns, V., Come, S. E., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.6660 · Cited by 436
Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide
Cochrane, D. R., Bernales, S., Jacobsen, B. M., Cittelly, D. M., Howe, E. N., D’Amato, N. C., Spoelstra, N. S., Edgerton, S. M., Jean, A., Guerrero, J., et al. (2014) · Breast Cancer Research · doi:10.1186/bcr3599 · Cited by 427
Turner, N., Lambros, M. B., Horlings, H. M., Pearson, A., Sharpe, R., Natrajan, R., Geyer, F. C., van Kouwenhove, M., Kreike, B., Mackay, A., et al. (2010) · Oncogene · doi:10.1038/onc.2009.489 · Cited by 416
A perspective on anti-EGFR therapies targeting triple-negative breast cancer.
Nakai, K., Hung, M., & Yamaguchi, H. (2016) · Europe PMC (PubMed Central) · Cited by 416
Cauley, J. A., Lucas, F. L., Kuller, L. H., Stone, K., Browner, W., Cummings, S. R., & for the Study of Osteoporotic Fractures Research Group (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-4_part_1-199902160-00004 · Cited by 409
Androgen Receptor Inhibits Estrogen Receptor-α Activity and Is Prognostic in Breast Cancer
Peters, A. A., Buchanan, G., Ricciardelli, C., Bianco-Miotto, T., Centenera, M. M., Harris, J. M., Jindal, S., Segara, D., Jia, L., Moore, N. L., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0452 · Cited by 405
Hahnen, E., Lederer, B., Hauke, J., Loibl, S., Kröber, S., Schneeweiss, A., Denkert, C., Fasching, P. A., Blohmer, J. U., Jackisch, C., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.1007 · Cited by 384
Vera-Badillo, F. E., Templeton, A. J., de Gouveia, P., Diaz-Padilla, I., Bedard, P. L., Al-Mubarak, M., Seruga, B., Tannock, I. F., Ocana, A., & Amir, E. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt319 · Cited by 370
Baselga, J., Gómez, P., Greil, R., Braga, S., Climent, M. A., Wardley, A. M., Kaufman, B., Stemmer, S. M., Pêgo, A., Chan, A., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.2408 · Cited by 363
Fulford, L. G., Easton, D. F., Reis‐Filho, J. S., Sofronis, A., Gillett, C. E., Lakhani, S. R., & Hanby, A. (2006) · Histopathology · doi:10.1111/j.1365-2559.2006.02453.x · Cited by 352
Lehmann, B. D., Bauer, J. A., Schafer, J. M., Pendleton, C. S., Tang, L., Johnson, K. C., Chen, X., Balko, J. M., Gómez, H., Arteaga, C. L., et al. (2014) · Breast Cancer Research · doi:10.1186/s13058-014-0406-x · Cited by 342
Functionally recurrent rearrangements of the MAST kinase and Notch gene families in breast cancer
Robinson, D. R., Kalyana-Sundaram, S., Wu, Y.-M., Shankar, S., Cao, X., Ateeq, B., Asangani, I. A., Iyer, M., Maher, C. A., Grasso, C. S., et al. (2011) · Nature Medicine · doi:10.1038/nm.2580 · Cited by 340
Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients
Byrski, T., Huzarski, T., Dent, R., Gronwald, J., Zuziak, D., Cybulski, C., Kladny, J., Gorski, B., Lubinski, J., & Narod, S. A. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-0128-9 · Cited by 340
Subtyping of triple‐negative breast cancer: Implications for therapy
Abramson, V. G., Lehmann, B. D., Ballinger, T. J., & Pietenpol, J. A. (2015) · Cancer · doi:10.1002/cncr.28914 · Cited by 333
Geisler, S. B., Lønning, P. E., Aas, T., Johnsen, H., Fluge, Ø., Haugen, D. F., Lillehaug, J. R., Akslen, L. A., & Børresen‐Dale, A. (2001) · PubMed · Cited by 326
Dawson, S.-J., Makretsov, N., Blows, F. M., Driver, K. E., Provenzano, E., Le Quesne, J., Baglietto, L., Severi, G., Giles, G. G., McLean, C. A., et al. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605736 · Cited by 317
Gene Expression Profiling Shows Medullary Breast Cancer Is a Subgroup of Basal Breast Cancers
Bertucci, F., Finetti, P., Cervera, N., Charafe-Jauffret, E., Mamessier, E., Adélaïde, J., Debono, S., Houvenaeghel, G., Maraninchi, D., Viens, P., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0031 · Cited by 310
High EGFR gene copy number predicts poor outcome in triple-negative breast cancer
Park, H. S., Jang, M. H., Kim, E. J., Kim, H. J., Lee, H. J., Kim, Y. J., Kim, J. H., Kang, E., Kim, S.-W., Kim, I. A., et al. (2014) · Modern Pathology · doi:10.1038/modpathol.2013.251 · Cited by 300
TP53mutation status and gene expression profiles are powerful prognostic markers of breast cancer
Langerød, A., Zhao, H., Borgan, Ø., Nesland, J. M., Bukholm, I. R., Ikdahl, T., Kåresen, R., Børresen-Dale, A.-L., & Jeffrey, S. S. (2007) · Breast Cancer Research · doi:10.1186/bcr1675 · Cited by 291
Fedele, C. G., Ooms, L. M., Ho, M., Vieusseux, J., O'Toole, S. A., Millar, E. K., Lopez-Knowles, E., Sriratana, A., Gurung, R., Baglietto, L., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1015245107 · Cited by 283
Single-Cell Dynamics Determines Response to CDK4/6 Inhibition in Triple-Negative Breast Cancer
Asghar, U. S., Barr, A. R., Cutts, R., Beaney, M., Babina, I., Sampath, D., Giltnane, J., Lacap, J. A., Crocker, L., Young, A., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0369 · Cited by 268
Tolaney, S. M., Boucher, Y., Duda, D. G., Martin, J. D., Seano, G., Ancukiewicz, M., Barry, W. T., Goel, S., Lahdenrata, J., Isakoff, S. J., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1518808112 · Cited by 258
García-Martínez, E., Gil, G. L., Benito, A. C., González-Billalabeitia, E., Conesa, M. A. V., García, T. G., García-Garre, E., Vicente, V., & de la Peña, F. A. (2014) · Breast Cancer Research · doi:10.1186/s13058-014-0488-5 · Cited by 253
Chacón, R. D., & Costanzo, M. V. (2010) · Breast Cancer Research · doi:10.1186/bcr2574 · Cited by 239
Barton, V. N., D'Amato, N. C., Gordon, M. A., Lind, H. T., Spoelstra, N. S., Babbs, B. L., Heinz, R. E., Elias, A., Jedlicka, P., Jacobsen, B. M., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0926 · Cited by 239
PI3K-AKT-mTOR inhibitors in breast cancers: From tumor cell signaling to clinical trials
Dey, N., De, P., & Leyland-Jones, B. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.037 · Cited by 229
Heitz, F., Harter, P., Lueck, H.-J., Fissler-Eckhoff, A., Lorenz-Salehi, F., Scheil-Bertram, S., Traut, A., & Bois, A. D. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2009.06.027 · Cited by 224
Rugo, H. S., Barry, W. T., Moreno-Aspitia, A., Lyss, A. P., Cirrincione, C., Leung, E., Mayer, E. L., Naughton, M., Toppmeyer, D., Carey, L. A., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.5298 · Cited by 222
Loibl, S., Müller, B. M., von Minckwitz, G., Schwabe, M., Roller, M., Darb-Esfahani, S., Ataseven, B., du Bois, A., Fissler-Eckhoff, A., Gerber, B., et al. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1715-8 · Cited by 211
Pareja, F., Geyer, F. C., Marchiò, C., Burke, K. A., Weigelt, B., & Reis-Filho, J. S. (2016) · npj Breast Cancer · doi:10.1038/npjbcancer.2016.36 · Cited by 206
Androgen Receptor Levels and Association with PIK3CA Mutations and Prognosis in Breast Cancer
Gonzalez-Angulo, A. M., Stemke-Hale, K., Palla, S. L., Carey, M., Agarwal, R., Meric-Berstam, F., Traina, T. A., Hudis, C., Hortobagyi, G. N., Gerald, W. L., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1763 · Cited by 205
Barrios, C. H., Liu, M.-C., Lee, S. C., Vanlemmens, L., Ferrero, J.-M., Tabei, T., Pivot, X., Iwata, H., Aogi, K., Lugo-Quintana, R., et al. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-0788-0 · Cited by 199
Kummar, S., Ji, J., Morgan, R., Lenz, H.-J., Puhalla, S. L., Belani, C. P., Gandara, D. R., Allen, D., Kiesel, B., Beumer, J. H., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2821 · Cited by 199
Han, H. S., Diéras, V., Robson, M., Palácová, M., Marcom, P. K., Jager, A., Bondarenko, I., Citrin, D., Campone, M., Telli, M. L., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdx505 · Cited by 194
Management of triple negative breast cancer
Oakman, C., Viale, G., & Di Leo, A. (2010) · The Breast · doi:10.1016/j.breast.2010.03.026 · Cited by 193
Triple-Negative Breast Cancer: Molecular Subtypes and New Targets for Therapy
Lehmann, B. D., Pietenpol, J. A., & Tan, A. R. (2015) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2015.35.e31 · Cited by 176
The Evolution of Triple-Negative Breast Cancer: From Biology to Novel Therapeutics
Anders, C. K., Abramson, V. G., Tan, T. J., & Dent, R. A. (2016) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_159135 · Cited by 172
He, J., Peng, R., Yuan, Z., Wang, S., Peng, J., Lin, G., Jiang, X., & Qin, T. (2012) · Medical Oncology · doi:10.1007/s12032-011-9832-0 · Cited by 170
Tutt, A., Ellis, P., Kilburn, L., Gilett, C., Pinder, S., Abraham, J., Barrett, S., Barrett-Lee, P., Chan, S., Cheang, M., et al. (2015) · Cancer Research · doi:10.1158/1538-7445.sabcs14-s3-01 · Cited by 167
Sharpe, R., Pearson, A., Herrera-Abreu, M. T., Johnson, D., Mackay, A., Welti, J. C., Natrajan, R., Reynolds, A. R., Reis-Filho, J. S., Ashworth, A., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2727 · Cited by 167
Androgen Receptor-Positive Triple Negative Breast Cancer: A Unique Breast Cancer Subtype
McGhan, L. J., McCullough, A. E., Protheroe, C. A., Dueck, A. C., Lee, J. J., Nunez-Nateras, R., Castle, E. P., Gray, R. J., Wasif, N., Goetz, M. P., et al. (2014) · Annals of Surgical Oncology · doi:10.1245/s10434-013-3260-7 · Cited by 167
Naderi, A., & Hughes-Davies, L. (2008) · Neoplasia · doi:10.1593/neo.08274 · Cited by 162
Understanding the biology of triple-negative breast cancer
Criscitiello, C., Azim, H. A., Schouten, P. C., Linn, S. C., & Sotiriou, C. (2012) · Annals of Oncology · doi:10.1093/annonc/mds188 · Cited by 162
CDK4/6-dependent activation of DUB3 regulates cancer metastasis through SNAIL1
Liu, T., Yu, J., Deng, M., Yin, Y., Zhang, H., Luo, K., Qin, B., Li, Y., Wu, C., Ren, T., et al. (2017) · Nature Communications · doi:10.1038/ncomms13923 · Cited by 161
Inactivation of p53 in breast cancers correlates with stem cell transcriptional signatures
Mizuno, H., Spike, B. T., Wahl, G. M., & Levine, A. J. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1017001108 · Cited by 160
Teng, Y. H.-F., Tan, W.-J., Thike, A., Cheok, P. Y., Tse, G. M.-K., Wong, N.-S., Yip, G. W. C., Bay, B., & Tan, P. (2011) · Breast Cancer Research · doi:10.1186/bcr2857 · Cited by 154
Choi, J. E., Kang, S. H., Lee, S. J., & Bae, Y. K. (2014) · Annals of Surgical Oncology · doi:10.1245/s10434-014-3984-z · Cited by 153
Gerber, B., Loibl, S., Eidtmann, H., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt361 · Cited by 153
Tang, D., Xu, S., Zhang, Q., & Zhao, W. (2011) · Medical Oncology · doi:10.1007/s12032-011-9948-2 · Cited by 146
Walker, A. J., Wedam, S. B., Amiri‐Kordestani, L., Bloomquist, E. W., Tang, S., Sridhara, R., Chen, W., Palmby, T. R., Zirkelbach, J. F., Fu, W., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0493 · Cited by 133
Engel, C., Rhiem, K., Hahnen, E., Loibl, S., Weber, K. E., Seiler, S., Zachariae, S., Hauke, J., Wappenschmidt, B., Waha, A., et al. (2018) · BMC Cancer · doi:10.1186/s12885-018-4029-y · Cited by 130
Barton, V. N., D’Amato, N. C., Gordon, M. A., Christenson, J. L., ELIAS, A. D., & Richer, J. K. (2015) · Hormones and Cancer · doi:10.1007/s12672-015-0232-3 · Cited by 129
Qu, Q., Mao, Y., Fei, X., & Shen, K. (2013) · PLoS ONE · doi:10.1371/journal.pone.0082650 · Cited by 127
Bcl2 Negatively Regulates DNA Double-Strand-Break Repair through a Nonhomologous End-Joining Pathway
Wang, Q., Gao, F., May, W. S., Zhang, Y., Flagg, T. O., & Deng, X. (2008) · Molecular Cell · doi:10.1016/j.molcel.2007.12.029 · Cited by 122
The Role of the Androgen Receptor in Triple-Negative Breast Cancer
Shah, P. D., Gucalp, A., & Traina, T. A. (2013) · Women s Health · doi:10.2217/whe.13.33 · Cited by 121
Nabholtz, J., Abrial, C., Mouret‐Reynier, M., Dauplat, M.-M., Weber, B. E., Gligorov, J., Forest, A. M., Trédan, O., Vanlemmens, L., Petit, T., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu183 · Cited by 121
The prognostic impact of age in patients with triple-negative breast cancer
Liedtke, C., Hess, K., Karn, T., Rody, A., Kiesel, L., Hortobágyi, G. N., Pusztai, L., & Gonzalez-Angulo, A. M. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2461-x · Cited by 120
De, P. K., Sun, Y., Carlson, J. H., Friedman, L. S., Leyland-Jones, B. R., & Dey, N. (2014) · Neoplasia · doi:10.1593/neo.131694 · Cited by 113
Aleskandarany, M. A., Abduljabbar, R. F., Ashankyty, I., Elmouna, A., Jerjees, D. A., Ali, S., Buluwela, L., Diez, M., Caldas, C., Green, A. R., et al. (2016) · Breast Cancer Research and Treatment · doi:10.1007/s10549-016-3934-5 · Cited by 111
Hussain, S. P., & Harris, C. C. (2006) · Journal of Nippon Medical School · doi:10.1272/jnms.73.54 · Cited by 110
Abdel-Fatah, T. M. A., Perry, C., Dickinson, P. D., Ball, G., Moseley, P. M., Madhusudan, S., Ellis, I. O., & Chan, S. Y. T. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt277 · Cited by 94
Predictors of Chemosensitivity in Triple Negative Breast Cancer: An Integrated Genomic Analysis
Jiang, T., Shi, W., Wali, V. B., Pongor, L. S., Li, C., Lau, R., Győrffy, B., Lifton, R. P., Symmans, W. F., Pusztai, L., et al. (2016) · PLoS Medicine · doi:10.1371/journal.pmed.1002193 · Cited by 84
Examining the Role of Cyclin D1 in Breast Cancer
Velasco-Velázquez, M. A., Li, Z., Casimiro, M. C., Loro, E., Homsi, N., & Pestell, R. G. (2011) · Future Oncology · doi:10.2217/fon.11.56 · Cited by 81
p53 as a Specific Prognostic Factor in Triple-negative Breast Cancer
Chae, B. J., Bae, J. S., Lee, A., Park, W. C., Seo, Y., Song, B. J., Kim, J. S., & Jung, S. S. (2009) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyp007 · Cited by 80
Rajput, S., Khera, N., Guo, Z., Hoog, J., Li, S., & Ma, C. X. (2016) · Oncotarget · doi:10.18632/oncotarget.10870 · Cited by 78
A Ki67/BCL2 index based on immunohistochemistry is highly prognostic in ER‐positive breast cancer
Ali, H. R., Dawson, S., Blows, F. M., Provenzano, E., Leung, S. C. Y., Nielsen, T. O., Pharoah, P. D. P., & Caldas, C. (2011) · The Journal of Pathology · doi:10.1002/path.2976 · Cited by 76
Targeting the androgen receptor in triple-negative breast cancer: current perspectives
Mina, A. A., Yoder, R., & Sharma, P. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s126051 · Cited by 71
Toyama, T., Yamashita, H., Kondo, N., Okuda, K., Takahashi, S., Sasaki, H., Sugiura, H., Iwase, H., & Fujii, Y. (2008) · BMC Cancer · doi:10.1186/1471-2407-8-309 · Cited by 70
Kim, J., Park, K., Jung, H. H., Lee, E., Cho, E. Y., Lee, K. H., Bae, S. Y., Lee, S. K., Kim, S. W., Lee, J. E., et al. (2016) · Cancer Research and Treatment · doi:10.4143/crt.2015.430 · Cited by 70
Zhu, A., Li, Y., Song, W., Xu, Y., Yang, F., Zhang, W., Yin, Y., & Guan, X. (2016) · Cellular Physiology and Biochemistry · doi:10.1159/000443052 · Cited by 67
Role of androgen receptor in triple-negative breast cancer, The
Barton, V. N. (2016) · doi:10.25677/m1rx-de67 · Cited by 67
Molecular Pathways: PI3K Pathway Targets in Triple-Negative Breast Cancers
Gordon, V. L., & Banerji, S. O. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0274 · Cited by 66
Comprehensive analysis of PTEN status in breast carcinomas
Jones, N. B., Bonnet, F., Sfar, S., Lafitte, M., Lafon, D., Sierankowski, G., Brouste, V., Banneau, G., de Lara, C. T., Debled, M., et al. (2013) · International Journal of Cancer · doi:10.1002/ijc.28021 · Cited by 62
The prognostic value of BRCA1 promoter methylation in early stage triple negative breast cancer
Sharma, P., Stecklein, S. R., Kimler, B. F., Sethi, G., Petroff, B. K., Phillips, T. A., Tawfik, O. W., Godwin, A. K., & Jensen, R. A. (2014) · journal of cancer therapeutics and research · doi:10.7243/2049-7962-3-2 · Cited by 62
Coates, A. S., Millar, E. K. A., O'Toole, S. A., Molloy, T. J., Viale, G., Goldhirsch, A., Regan, M. M., Gelber, R. D., Sun, Z., Castiglione‐Gertsch, M., et al. (2012) · Breast Cancer Research · doi:10.1186/bcr3348 · Cited by 62
Neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients
Gronwald, J., Byrski, T., Huzarski, T., Dent, R. A., Bielicka, V., Zuziak, D., Wiśniowski, R., Lubiński, J., & Narod, S. A. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.502 · Cited by 61
Beg, S., Siraj, A. K., Prabhakaran, S., Jehan, Z., Ajarim, D. S., Al‐Dayel, F., Tulbah, A. M., & Al-Kuraya, K. S. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3430-3 · Cited by 59
Trédan, O., Campone, M., Jassem, J., et al. (2014) · Clinical Breast Cancer · doi:10.1016/j.clbc.2014.07.007 · Cited by 58
Somatic mutations in cancer prognosis and prediction: lessons from TP53 and EGFR genes
Olivier, M., & Tanière, P. (2010) · Current Opinion in Oncology · doi:10.1097/cco.0b013e3283412dfa · Cited by 57
Poly(ADP-ribose) polymerase inhibition: a new direction for BRCAand triple-negative breast cancer?
Plummer, R. (2011) · Breast Cancer Research · doi:10.1186/bcr2877 · Cited by 55
Powell, E., Shao, J., Yuan, Y., Chen, H.-C., Cai, S., Echeverria, G. V., Mistry, N. A., Decker, K. F., Schlosberg, C., Do, K.-A., et al. (2016) · Breast Cancer Research · doi:10.1186/s13058-016-0673-9 · Cited by 51
Litton, J. K., Rugo, H. S., Ettl, J., Hurvitz, S. A., Gonçalvès, A., Lee, K.-H., Fehrenbacher, L., Yerushalmi, R., Mina, L., Martín, M., et al. (2018) · Cancer Research · doi:10.1158/1538-7445.sabcs17-gs6-07 · Cited by 50
Shaver, T. M., Lehmann, B. D., Beeler, J. S., Li, C.-I., Li, Z., Jin, H., Stricker, T. P., Shyr, Y., & Pietenpol, J. A. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0058 · Cited by 46
Végran, F., Rebucci, M., Chevrier, S., Cadouot, M., Boidot, R., & Lizard‐Nacol, S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0055103 · Cited by 43
Bouchalová, K., Svoboda, M., Kharaishvili, G., Vrbková, J., Bouchal, J., Trojanec, R., Koudeláková, V., Radová, L., Cwiertka, K., Hajdúch, M., et al. (2015) · Tumor Biology · doi:10.1007/s13277-015-3061-7 · Cited by 37
Self-citationTriple Negative Breast Cancer - BCL2 in Prognosis and Prediction. Review
Bouchalová, K., Kharaishvili, G., Bouchal, J., et al. (2014) · Current Drug Targets · doi:10.2174/1389450115666141106151143 · Cited by 37
Pusztai, L., Krishnamurty, S., Cardona, J., Sneige, N., Esteva, F. J., Volchenok, M., Breitenfelder, P., Kau, S., Takayama, S., Krajewski, S., et al. (2004) · Cancer Investigation · doi:10.1081/cnv-120030213 · Cited by 35
Chen, X., Yuan, Y., Garfield, D. H., Wu, J., Huang, O., & Shen, K. (2014) · PLoS ONE · doi:10.1371/journal.pone.0108405 · Cited by 35
SAKUMA, K., Kurosumi, M., Oba, H., Kobayashi, Y., Takei, H., Inoue, K., Tabei, T., & Oyama, T. (2011) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2011.212 · Cited by 30
Kim, Y., Kim, J., Lee, H. D., Jeong, J., Lee, W., & Lee, K. (2013) · PLoS ONE · doi:10.1371/journal.pone.0079014 · Cited by 28
Tan, S., Sapari, N. S., Miao, H., Hartman, M., Loh, M. C. S., Chng, W. J., Iau, P. C. T., Buhari, S. A., Soong, R., & Lee, S. C. (2015) · PLoS ONE · doi:10.1371/journal.pone.0142466 · Cited by 23
Yardley, D. A., Shipley, D. L., Peacock, N. W., Shastry, M., Midha, R., Priego, V. M., & Hainsworth, J. D. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3482-4 · Cited by 17
Cited by
Triple Negative Breast Cancer Treatment Options and Limitations: Future Outlook
Obidiro, O., Battogtokh, G., & Akala, E. O. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15071796 · Cited by 511
Gupta, G. K., Collier, A. L., Lee, D., Hoefer, R. A., Zheleva, V., Siewertsz van Reesema, L. L., Tang-Tan, A. M., Guye, M. L., Chang, D. Z., Winston, J. S., et al. (2020) · Cancers · doi:10.3390/cancers12092392 · Cited by 331
Sun, X., Tang, H., Chen, Y., Chen, Z., Hu, Z., Cui, Z., Tao, Y., Yuan, J., Fu, Y., Zhuang, Z., et al. (2023) · Nature Cancer · doi:10.1038/s43018-023-00535-w · Cited by 66
Metadata
- Authors
- Sporikova, Z., Koudelakova, V., Trojanec, R., & Hajduch, M.
- Venue
- Clinical Breast Cancer
- Publisher
- Elsevier BV
- Published
- 2018-10
- Volume
- 18
- Issue
- 5
- Pages
- e841-e850
- ISSN
- 1526-8209 (ISSN-L)
- OpenAlex
- W2887014156
- Cited by
- 262
- References
- 148
- FWCI
- 6.57
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.